Miaomiao Gou

Dec 12, 2023 | futuremedicine.com | Miaomiao Gou |Yong Zhang |Tongtong Qu |Ru Jia

Papers of special note have been highlighted as:• of interest; •• of considerable interest• None Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial .